A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
NCT03888105
Recruiting
This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more about the safety of odronextamab. The study is looking at several other research questions, including: * To see if odronextamab works to destroy cancer cells * Side effects that may be experienced by people taking odronextamab * How odronextamab works... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Rush University Medical Center, Chicago, Illinois +139 locations
Conditions: B-cell Non-Hodgkin Lymphoma (B-NHL)
Register for Updates
Motor rECovery witH eArly imagiNg In STroke
NCT04165616
Recruiting
This study will contribute to the field of stroke rehabilitation research by expanding the investigator's understanding of the neural mechanisms responsible for the development and expression of abnormal flexion synergy, a primary movement impairment due to stroke. The study will longitudinally evaluate motor tract morphology and motor impairment/function in an attempt to develop early neuroimaging-based predictors of the development of flexion synergy and its impact on reaching and hand recover... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/24/2025
Locations: Department of Physical Therapy and Human Movement Sciences, Chicago, Illinois +2 locations
Conditions: Stroke
Register for Updates
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750
Recruiting
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/24/2025
Locations: Hoag Cancer Center, Irvine, California +73 locations
Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Register for Updates
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
NCT04829357
Recruiting
The objective of this single arm, post market, clinical study is to evaluate the performance of Gynecare TVT ABBREVO® Continence System in women undergoing Mid-urethral sling surgery for Stress Urinary Incontinence (SUI).
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
04/24/2025
Locations: Institute for Female Pelvic Medicine, North Wales, Pennsylvania +4 locations
Conditions: Stress Urinary Incontinence
Register for Updates
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
NCT05019703
Recruiting
This phase II trial studies the effect of atezolizumab and cabozantinib in treating adolescents and young adults with osteosarcoma that has come back (recurrent) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/24/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Locally Advanced Osteosarcoma, Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma, Unresectable Osteosarcoma
Register for Updates
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05077904
Recruiting
The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/24/2025
Locations: Ep0162 50506, Phoenix, Arizona +161 locations
Conditions: Stereotypical Prolonged Seizures
Register for Updates
AutoInflammatory Disease Alliance Registry (AIDA)
NCT05200715
Recruiting
Autoinflammatory diseases (AID) are clinical entities characterized by recurrent inflammatory attacks in absence of infection, neoplasm or deregulation of the adaptive immune system. Among them, hereditary periodic syndromes, also known as monogenic AID, represent the prototype of this disease group, caused by mutations in genes involved in the regulation of innate immunity, inflammation and cell death. Based on recent experimental acquisitions in the field of monogenic AID, several immunologic... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/24/2025
Locations: National Human Genome Research Institute, Bethesda, Maryland +99 locations
Conditions: Hereditary Autoinflammatory Diseases, Schnitzler Syndrome, Behcet Syndrome, PFAPA Syndrome, Still Disease, Autoinflammatory Syndrome, Unspecified, Uveitis, Scleritis, Vexas Syndrome, Spondyloarthritis (SpA), Castleman Disease
Register for Updates
Promoting Alcohol Treatment Engagement Post-hospitalization
NCT05338151
Recruiting
This study is a 3-arm randomized clinical trial to evaluate the effectiveness of hospital-initiated Alcohol Use Disorder treatment, involving a Brief Negotiated Interview (with referral and telephone booster) alone, BNI+facilitated provision of MAUD, BNI+facilitated provision of MAUD+CBT4CBT on AUD treatment engagement, alcohol use and healthcare utilization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Alcohol Use Disorder
Register for Updates
Evaluate REC-4881 in Patients With FAP
NCT05552755
Recruiting
This is a multicenter, two-part trial in participants with Familial Adenomatous Polyposis (FAP).
Gender:
ALL
Ages:
55 years and above
Trial Updated:
04/24/2025
Locations: Mayo Clinic - Scottsdale, Scottsdale, Arizona +16 locations
Conditions: Familial Adenomatous Polyposis
Register for Updates
Life's End Benefits of cannaBidiol and tetrahYdrocannabinol
NCT05644262
Recruiting
This is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) compared to placebo over 12 weeks. This study is designed to test the hypothesis that treatment with an oral combination of THC/CBD will reduce agitation hospice care-eligible patients with agitation and dementia as measured by the Cohen Mansfield Agitation Inventory (CMAI) when compared to placebo at 2 weeks. This study will enroll approximat... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
04/24/2025
Locations: The Neuron Clinic, Chula Vista, California +12 locations
Conditions: Agitation, Dementia
Register for Updates
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
NCT05782907
Recruiting
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how safe and effective Upadacitinib is in treating pediatric participants with UC. Adverse events and change in disease activity will be assessed. Upadacitinib (RINVOQ) is a drug approved in adults for moderate- to severely active UC and is being developed for moderate- to severely active UC in pediatric participa... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
04/24/2025
Locations: Phoenix Children's Hospital /ID# 250135, Phoenix, Arizona +83 locations
Conditions: Ulcerative Colitis
Register for Updates
Metformin for Fibromyalgia Symptoms (INFORM Trial)
NCT05900466
Recruiting
The main purpose of the project is to evaluate the safety and efficacy of low dose metformin for improving symptoms associated with fibromyalgia syndrome (FMS) via modulating neuroinflammatory pathways. The investigators hypothesize that FMS patients in the low-dose metformin conditions will show greater improvement in FMS symptoms than those who are in the placebo group. Further, the investigators hypothesize that metformin will increase phosphorylated AMPK in peripheral immune cells of FMS pat... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/24/2025
Locations: University of Utah, Salt Lake City, Utah
Conditions: Fibromyalgia Syndrome
Register for Updates